TRVI
- Trevi Therapeutics, Inc.
()
Overview
Company Summary
Trevi Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for neurological disorders. Specifically, they are dedicated to addressing the unmet needs of patients suffering from neurological conditions that are commonly associated with chronic itch or pruritus.
Trevi Therapeutics is primarily focused on the development of their lead product candidate, Nalbuphine ER, which is an extended-release formulation of nalbuphine. Nalbuphine is a medication that has been used for several decades as an effective analgesic (pain reliever). However, Trevi Therapeutics is repurposing this drug to potentially treat conditions such as prurigo nodularis, chronic liver disease-associated pruritus, and other chronic pruritus conditions.
Chronic pruritus is characterized by persistent itching that can significantly impact patients' quality of life. Currently, there are limited treatment options available, and the ones that exist often come with side effects or provide inadequate relief. Trevi Therapeutics aims to provide an innovative and effective treatment option by leveraging the unique properties of Nalbuphine ER.
The company has conducted clinical trials to evaluate the safety and efficacy of Nalbuphine ER. Their goal is to demonstrate the drug's potential to alleviate itch and improve the overall well-being of patients suffering from chronic pruritus. If successful, Trevi Therapeutics aims to obtain regulatory approvals and ultimately commercialize Nalbuphine ER for these neurological conditions.
In summary, Trevi Therapeutics is a biopharmaceutical company specializing in the development of therapies for neurological disorders, with a particular focus on chronic pruritus conditions. Their lead product candidate, Nalbuphine ER, has the potential to address the unmet needs of patients by providing a more effective and well-tolerated treatment option.